News
TCON
0.1830
+10.17%
0.0169
Weekly Report: what happened at TCON last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at TCON last week (0212-0216)?
Weekly Report · 02/19 09:49
Weekly Report: what happened at TCON last week (0205-0209)?
Weekly Report · 02/12 09:45
Weekly Report: what happened at TCON last week (0129-0202)?
Weekly Report · 02/05 09:48
Weekly Report: what happened at TCON last week (0122-0126)?
Weekly Report · 01/29 09:45
Weekly Report: what happened at TCON last week (0115-0119)?
Weekly Report · 01/22 09:46
Weekly Report: what happened at TCON last week (0108-0112)?
Weekly Report · 01/15 09:45
Weekly Report: what happened at TCON last week (0101-0105)?
Weekly Report · 01/08 09:46
Weekly Report: what happened at TCON last week (1225-1229)?
Weekly Report · 01/01 09:44
Weekly Report: what happened at TCON last week (1218-1222)?
Weekly Report · 12/25/2023 09:48
Buy Rating for TRACON Pharmaceuticals on Envafolimab’s Promising Trial Outcomes and Strong Market Potential
Edward White, an analyst from H.C. Wainwright, maintained the Buy rating on TRACON Pharmaceuticals (TCON – Research Report). The associated price target is $7.00. White has given his Buy rating to the company's promising drug, envafolimab. The pivotal Phase 2 ENVASARC trial is advancing well.
TipRanks · 12/20/2023 14:45
TRACON Pharmaceuticals Provides Update On Ongoing ENVASARC Pivotal Phase 2 Trial; Objective Response Rate By Investigator Review Increased To 15% Since Interim Analysis In September
Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024. The ongoing pivotal Phase 2 ENvASARC trial has enrolled more than 70 of the 80 planned patients.
Benzinga · 12/20/2023 13:03
Tracon Pharmaceu: Current report
Press release · 12/19/2023 23:52
Weekly Report: what happened at TCON last week (1211-1215)?
Weekly Report · 12/18/2023 09:50
JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)
Soumit Roy maintains a Hold rating on TRACON Pharmaceuticals. The company's shares closed yesterday at $0.17. Roy has an average return of -5.0% and a 26.02% success rate on recommended stocks. The stock has an analyst consensus of Moderate Buy with a price target of $4.
TipRanks · 12/13/2023 13:55
Weekly Report: what happened at TCON last week (1204-1208)?
Weekly Report · 12/11/2023 09:49
Tracon Pharmaceu: Current report
Press release · 12/08/2023 23:08
More
Webull provides a variety of real-time TCON stock news. You can receive the latest news about Tracon Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About TCON
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States.